News & Insights Search

Most companies treat the Form 483 response as the chance to close the loop after an FDA inspection. In many warning letters, FDA reaches a different conclusion: the company responded, FDA reviewed the response, and the agency still found the answer incomplete.

Audit-ready organizations don't wait for an audit to start checking whether their quality system works.

Regulatory teams face increasing pressure to be agile, simultaneously managing submissions of varying size and complexity while meeting evolving global health authority (requirements. However, siloed systems often hinder visibility into submission data and progress.

Bringing publishing in-house can reduce submission timelines by as much as 50%. To reap the benefits of continuous publishing, regulatory teams need a clear plan to effectively support end users and ease the change management burden.

Real-world evidence (RWE) can enhance our understanding of the safety, performance, and effectiveness of medical technologies, and health authorities are increasingly recognizing its benefits in informing regulatory decisions across the product lifecycle.

To be effective, AI must be applied precisely to purpose and guided by human expertise. In this article, we'll discuss how life sciences companies and the patients they serve can benefit from this transformative technology.

Continuous publishing allows for the simultaneous and iterative completion of traditional downstream publishing tasks alongside traditional upstream planning and authoring tasks. This speeds and streamlines the entire submission preparation process and encourages more focus on the quality of submissions.

Today, there is an intentional shift underway to uplift the patient voice and encourage the pharmaceutical and medtech industry to more closely partner with patients to advance safety science innovation to improve health outcomes.

Biopharma companies are accelerating submission timelines with a continuous publishing approach. Learn how they proactively mitigate risk and address issues earlier in the submission cycle so that publishers can review, analyze, and submit a quality application without teams working inefficiently or overtime.